Summary: Higher baseline levels of naturally occurring anti‑NMDAR1 antibodies in the blood were linked to substantially lower risk of developing post‑deployment depressive and PTSD symptoms among service members with a lifetime history of traumatic brain injury (TBI). In mechanistic mouse experiments, antibody isotype size explained divergent effects: small IgG antibodies penetrated synaptic clefts and impaired memory, while large IgM antibodies could not enter synapses and instead bound extrasynaptic NMDA receptors, reducing excitotoxic injury after TBI and providing long‑lasting neuroprotection.
Key Findings
- Biomarker of psychiatric resilience: Active‑duty Marines in the top quartile for circulating anti‑NMDAR1 antibodies showed about 25% lower depression scores and 22% lower PTSD symptom scores after deployment compared with those in the lowest quartile, specifically among individuals with a lifetime history of TBI.
- Symptom‑specific protection: Elevated antibody levels were associated with reduced rates of moderate‑to‑severe depression and lower post‑deployment psychotropic medication use, but they were not associated with generalized anxiety symptoms.
- Durable serum presence: Anti‑NMDAR1 antibodies were detectable for more than 12 months, indicating that high expression may reflect a stable biological trait rather than a transient response.
- Isotype size determines effect: Preclinical work found that small IgG isotypes enter synaptic clefts and can disrupt memory (as in anti‑NMDAR encephalitis), whereas larger IgM isotypes are excluded from synapses and preferentially target extrasynaptic NMDA receptors.
- Protection from excitotoxic injury: After TBI, pathological glutamate release hyperactivates extrasynaptic NMDA receptors and triggers secondary neuronal injury. Large IgM anti‑NMDAR1 antibodies appear to shield these extrasynaptic sites, blunting excitotoxic cascades in a manner comparable to longer‑acting receptor antagonists.
Source: UCSD
Background: Each year, an estimated 20 million people worldwide sustain a concussion or other form of traumatic brain injury. TBI increases the risk of developing depression, anxiety and post‑traumatic stress disorder (PTSD) by two‑ to four‑fold, yet many people who experience TBI do not go on to develop psychiatric symptoms. Identifying biological factors that promote resilience could improve risk stratification and point to novel therapeutic strategies.
Researchers at the University of California San Diego School of Medicine and the VA San Diego Healthcare System investigated whether naturally occurring antibodies against the NMDA receptor subunit NMDAR1 are associated with psychiatric outcomes after TBI. Anti‑NMDAR1 antibodies target NMDA receptors, which play a central role in memory formation and synaptic plasticity. Although pathogenic anti‑NMDAR1 antibodies are implicated in rare autoimmune encephalitis that produces memory deficits, the study tested the hypothesis that some naturally occurring anti‑NMDAR1 antibodies—depending on isotype—may confer protection against TBI‑related injury.
The team analyzed pre‑ and post‑deployment blood samples and clinical assessments from 1,025 male active‑duty Marines enrolled in the Marine Resiliency Study II who deployed to Afghanistan between 2011 and 2013. Researchers measured plasma anti‑NMDAR1 autoantibody levels before deployment and assessed post‑deployment psychiatric symptoms using standardized instruments.
- Among the 606 Marines with a lifetime history of TBI, those in the top quartile for pre‑deployment anti‑NMDAR1 antibody levels had approximately 25% lower depressive symptoms and 22% lower PTSD symptom scores after deployment than those in lower quartiles.
- High antibody levels were associated with a significantly lower likelihood of reporting moderate‑to‑severe depression and with reduced use of psychotropic medications following deployment.
- Antibodies remained detectable in serum for over a year, supporting the idea that elevated levels represent a persistent trait.
- No meaningful association was observed between anti‑NMDAR1 levels and generalized anxiety symptoms, suggesting a degree of symptom specificity.
Mechanistic mouse studies complemented the human findings. Prior experiments that modeled anti‑NMDAR encephalitis in mice used smaller IgG‑type antibodies and reproduced cognitive deficits by allowing antibodies to access synaptic NMDA receptors. In contrast, naturally occurring IgM‑type antibodies—larger in molecular size—cannot fit into the synaptic cleft and instead bind extrasynaptic receptors. In mouse models of TBI, IgM anti‑NMDAR1 antibodies reduced excitotoxic injury and preserved cognitive function, consistent with the human association data.
These results raise the possibility that naturally occurring IgM anti‑NMDAR1 antibodies act as an endogenous neuroprotective factor after brain injury by blocking extrasynaptic NMDA receptors, a mechanism similar to the receptor antagonism underlying ketamine’s antidepressant effects but potentially longer lasting.
The authors emphasize that the human data are correlational and that further work is required to determine causality, to confirm whether antibodies access the central nervous system after TBI, and to test whether these findings generalize to other populations and to women.
Co‑senior authors include Victoria B. Risbrough, PhD, and Xianjin Zhou. Additional contributors listed in the publication include Melonie N. Vaughn, Jenna M. DeWit, Dewleen Baker, Dean T. Acheson, Susan B. Powell, Caroline M. Nievergelt and Kate A. Yurgil. Disclosure: Xianjin Zhou is named on a provisional patent filing by the University of California San Diego.
Funding: Supported in part by the National Institutes of Health (R01NS135620) and the U.S. Department of Veterans Affairs.
Editorial Notes
- Edited by a Neuroscience News editor.
- Journal paper reviewed in full and additional context added by staff.
About this Research
- Media Contact: Susanne Bard
- Source: UCSD
- Image credit: Image generated for Neuroscience News
- Original research (Open Access): Molecular Psychiatry (September 8, 2026). Title: “Natural anti–NMDAR1 autoantibodies are associated with lower risk for depression and PTSD symptoms after traumatic brain injury.” Authors: Melonie N. Vaughn, Dean T. Acheson, Susan B. Powell, Jenna M. DeWit, Kate A. Yurgil, Caroline M. Nievergelt, Dewleen Baker, Victoria B. Risbrough & Xianjin Zhou.
- DOI: 10.1038/s41380-026-03883-y
Abstract
Natural anti–NMDAR1 autoantibodies are associated with lower risk for depression and PTSD symptoms after traumatic brain injury
Traumatic brain injury increases the likelihood of later psychiatric symptoms such as depression, anxiety and PTSD, but individual outcomes vary widely and the biological bases of resilience are not well understood. Approximately 10% of people carry natural autoantibodies to the NMDA receptor, yet it has been unclear whether these antibodies modify psychiatric risk after TBI.
In this study, plasma anti‑NMDAR1 autoantibody levels were measured in male active‑duty service members before deployment. Post‑deployment outcomes included clinician‑administered PTSD assessments (CAPS‑IV), depression scores (BDI‑II) and anxiety scores (BAI). Lifetime TBI was associated with higher predicted post‑deployment depression, PTSD and anxiety symptoms (N = 606 with TBI, N = 419 without TBI).
Among individuals with TBI, higher pre‑deployment plasma levels of natural anti‑NMDAR1 autoantibodies were modestly but significantly associated with lower predicted post‑deployment depression (p = 0.0008) and PTSD symptoms (p = 0.0075), but not with anxiety. Membership in the top antibody quartile reduced predicted CAPS‑IV and BDI‑II scores by roughly 22% (~4 points) and 25% (~2 points), respectively, and was linked to lower prevalence of psychotropic medication use (p = 0.006). High antibody levels also predicted lower odds of post‑deployment moderate‑to‑severe depression (BDI‑II > 19; OR = 0.14, 95% CI 0.01–0.69, p = 0.014).
These findings suggest that natural anti‑NMDAR1 autoantibodies may serve as a resiliency factor for TBI‑associated risk of depression and PTSD symptoms, with potential neuroprotective actions. Future research should determine whether these antibodies access the central nervous system to suppress glutamate‑mediated excitotoxicity after TBI and whether results generalize across sexes and broader populations.